KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $903.5 million.

  • Ionis Pharmaceuticals' Total Current Liabilities rose 19663.72% to $903.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.5 million, marking a year-over-year increase of 19663.72%. This contributed to the annual value of $309.3 million for FY2024, which is 3096.97% down from last year.
  • As of Q3 2025, Ionis Pharmaceuticals' Total Current Liabilities stood at $903.5 million, which was up 19663.72% from $897.2 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Total Current Liabilities peaked at $903.5 million during Q3 2025, and registered a low of $228.4 million during Q1 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' median Total Current Liabilities value was $295.1 million (recorded in 2021), while the average stood at $363.1 million.
  • Per our database at Business Quant, Ionis Pharmaceuticals' Total Current Liabilities crashed by 5983.46% in 2021 and then surged by 19663.72% in 2025.
  • Ionis Pharmaceuticals' Total Current Liabilities (Quarter) stood at $240.6 million in 2021, then grew by 29.52% to $311.6 million in 2022, then soared by 43.82% to $448.1 million in 2023, then tumbled by 30.97% to $309.3 million in 2024, then skyrocketed by 192.08% to $903.5 million in 2025.
  • Its Total Current Liabilities was $903.5 million in Q3 2025, compared to $897.2 million in Q2 2025 and $250.3 million in Q1 2025.